摘要
目的比较尼莫地平与多奈哌齐对皮质下缺血性血管性认知障碍(SIVCI)患者的临床疗效。方法将90例SIVCI患者,随机分成3组,每组30例患者入选,2个实验组,分别为盐酸多奈哌齐组(给予多奈哌齐5 mg,每日1次,睡前口服)、尼莫地平组(尼莫地平30 mg,每日3次口服)及对照组。3组均使用基础药物治疗,基础药物为阿司匹林肠溶片100 mg每日1次;银杏叶提取物片,40 mg,每日3次。观察各组患者用药24周后各组间MoCA评分变化。结果与对照组比较,尼莫地平组患者服药24周后,MoCA评分提高1.60(P<0.05),有显著差异;与对照组比较,多奈哌齐组患者服药24周后MoCA评分提高4.26(P<0.0001),有显著差异。与尼莫地平组比较,多奈哌齐组患者服药24周后,MoCA评分平均提高2.51(P<0.0001),有显著差异。结论多奈哌齐与尼莫地平,均可用于治疗SIVCI,多奈哌齐疗效优于尼莫地平。
Objective To compare nimodipine and donepezil for their clinical effect on the patients with subeortical ischemie vascular cognitive impairment（SIVCI）. Methods 90 cases with SIVCI,randomly e- venly divided into 3 groups,are treated with aspirin（ 100 mg qd,po）and ginkgo biloba extract tablets（40 mg tid po） ; 2 experimental groups, hydrochloric donepezil group （ 5 mg/d donepezil, qn, po） and nimodipine group （ 30 mg Nimodipine tid po）. To observe the variety of MoCA score among groups after 24 weeks treatment. Re- suits To compare with the control group, the MoCA score of nimodipine and donepezil group increases 1.60 （P 〈0.05 ）,4.26 （P 〈 0. 0001 ）, repeetively, with significant differences. To compare with the nimodipine group, the MoCA score of donepezil group increases 2.51 （P 〈 0. 0001 ）with significant differences. Conclu- sion Both nimodipine and donepezil can be used to treat the patients with subcortical isehemie vascular cog- nitive impairment（SIVCI）. And donepezil is more effective than nimodipine on cognitive impairment.
出处
《血栓与止血学》
2012年第5期205-207,共3页
Chinese Journal of Thrombosis and Hemostasis
